长期使用H2受体对抗剂与前列腺癌风险之间的关联:台湾的一项病例对照研究
Shao-Fu Wang1, Yu-Chen Liu2,3, Phung-Anh Nguyen4,5,6,7
1School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Journal of Cancer
|January 26, 2026
概括
长期使用希斯胺-2受体抗剂,如西米蒂丁和拉尼蒂丁,可能会增加老年男性前列腺癌的风险. 法莫蒂丁没有显著的关联,表明年龄和药物特定的风险.
科学领域:
- 药学流行病学 药学流行病学
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 长期使用组胺-2受体抗剂 (H2RA) 与前列腺癌风险之间的联系尚未得到充分证实.
- 了解与H2RA使用相关的特定年龄风险对于患者安全至关重要.
研究的目的:
- 调查长期使用H2RA与前列腺癌风险之间的关联,重点关注特定年龄的影响.
- 根据特定的H2RA药物和患者年龄评估前列腺癌的风险.
主要方法:
- 全国范围的病例控制研究利用台湾的健康和福利数据科学中心数据库 (2003-2016).
- 匹配了43578例前列腺癌病例与174312例对照病例.
- 长期使用定义为60天或更长时间的累积暴露;用于分析的条件后勤回归.
主要成果:
- 长期使用H2RA与前列腺癌风险的轻微增加有关,特别是在65岁及以上的男性中 (aOR=1.087).
- 齐米蒂丁和拉尼蒂丁在老年男性中显示风险增加,而法莫蒂丁没有显著的关联.
- 在40-64岁的男性中,西米蒂丁的使用与风险降低有关 (aOR=0.865),这表明依赖年龄的影响.
结论:
- 长期使用cimetidine和ranitidine可能会增加老年男性前列腺癌的风险.
- 法莫蒂丁的使用与前列腺癌的风险增加无关.
- 在癌症药物流行病学研究中,药物特异性和年龄相关的风险评估是必要的.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
970
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
970
Drug-Receptor Interaction: Antagonist
5.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.2K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.3K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.3K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.5K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.5K


